News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alnylam Pharmaceuticals (ALNY) Grants Bioneer Corporation License To Kreutzer-Limmer Patents For The RNA Interference (RNAi) Research Products Market


5/24/2006 12:17:29 PM

CAMBRIDGE, Mass. & DAEJEON, South Korea--(BUSINESS WIRE)--May 24, 2006--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News), a leading RNAi therapeutics company, and Bioneer, Inc., a leading synthetic oligonucleotide manufacturer, announced today that Alnylam has granted Bioneer a non-exclusive license to provide RNAi research products under the Kreutzer-Limmer patent family. This patent family, owned exclusively by Alnylam, covers small interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells.

Read at press release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES